Companies › Enveda Therapeutics
1 active drug program in 3 registered trials: 3 Phase 2; Immunology, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ENV-294 | – | Phase 2 | Atopic Dermatitis (AD); Asthma; Atopic Dermatitis | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07298395 | ENV-294 | Phase 2 | Atopic Dermatitis (AD) | Immunology | Dec 2026 |
| NCT07301255 | ENV-294 | Phase 2 | Asthma | Respiratory | Dec 2026 |
| NCT07643766 | ENV-294 | Phase 2 | Atopic Dermatitis | Immunology | Dec 2027 |
No annotated target.
–
Prana Therapies Cumberland Pharmaceuticals ReAlta Life Sciences Avalyn Pharma Toll Biotech Co. Ltd. (Beijing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.